fluzoparib + mFOLFIRINOX

**fluzoparib + mFOLFIRINOX** is a combination therapy under investigation primarily for advanced and resectable pancreatic adenocarcinoma. Fluzoparib is a small molecule PARP (poly ADP ribose polymerase) inhibitor, developed to induce synthetic lethality in tumor cells with deficient homologous recombination repair (HRR) mechanisms, notably BRCA-mutated or HRR-deficient cancers. mFOLFIRINOX is a modified regimen of FOLFIRINOX chemotherapy, consisting of oxaliplatin, irinotecan, folinic acid (leucovorin), and fluorouracil (5-FU), but with adjustments to dosing or omission of the 5-FU bolus to improve tolerability. The combination aims to merge the DNA-damaging effects of chemotherapy with the DNA repair inhibition of fluzoparib, potentially enhancing anti-tumor efficacy. Clinical trials have focused on evaluating the safety, tolerability, and recommended phase II dose, as well as preliminary efficacy outcomes such as objective response and disease control rates in locally advanced/metastatic and perioperative (neoadjuvant/adjuvant) pancreatic cancer. Maintenance fluzoparib monotherapy often follows initial combination therapy[1][3][5].

Other names

fuzuloparib + mFOLFIRINOXfluzoparib plus modified FOLFIRINOX